Almirall, S.A. (ALM), a global pharmaceutical company dedicated to medical dermatology, today announced its participation in ...

Almirall has licensed an interleukin-2 (IL-2) drug from China's Simcere Pharma, joining the ranks of companies looking at blocking the cytokine as a way to treat autoimmune diseases.

Almirall has rolled out a new campaign for World Atopic Eczema Day, kicking off its “The T | Almirall has rolled out a new ...

Having been in development by Almirall and Eli Lilly and Company for moderate to severe AD, recent findings from a phase 3 trial for the first time have shown year-long (52-week) management of ...

A new dose-finding study supported the potential of the carbonic anhydrase inhibitor as an alternative to CPAP machines.

Almirall, the Spanish pharmaceutical company, is on the brink of securing European Union (EU) approval for its IL-13 inhibitor lebrikizumab, marketed as Ebglyss, for atopic dermatitis treatment.

The True Colours of Atopic Dermatitis” campaign is aimed at raising awareness of the physical symptoms and emotional impact of this highly prevalent chronic skin condition – affecting an estimated 2% ...

Eli Lilly and Company has announced the FDA approval of EBGLYSS for treating atopic dermatitis in adults and children over 12 ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Bray are now unbeaten in all eight fixtures that face Kerry in the past two years – winning seven times. NEARING PLAY OFF ...

BARCELONA, Spain, July 22, 2024--Almirall, S.A. (ALM) a global biopharmaceutical company based in Barcelona, today announced its financial results from the first half of 2024. Almirall continued to ...